This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perkins, J.
Right arrow Articles by Clavijo, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perkins, J.
Right arrow Articles by Clavijo, A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, November 2007, p. 1472-1482, Vol. 14, No. 11
1071-412X/07/$08.00+0     doi:10.1128/CVI.00227-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Use of a Standardized Bovine Serum Panel To Evaluate a Multiplexed Nonstructural Protein Antibody Assay for Serological Surveillance of Foot-and-Mouth Disease{triangledown} ,{dagger}

Julie Perkins,1* Satya Parida,2 and Alfonso Clavijo3

Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, California 94551,1 Institute for Animal Health, Pirbright Laboratory, Ash Road, Woking, Surrey GU24 0NF, United Kingdom,2 Canadian Food Inspection Agency, National Center for Foreign Animal Disease, 1015 Arlington Street, Winnipeg, Manitoba R3E 3M4, Canada3

Received 14 May 2007/ Returned for modification 23 July 2007/ Accepted 9 September 2007

Liquid array technology has previously been used to show proof of principle of a multiplexed nonstructural protein serological assay to differentiate foot-and-mouth disease virus-infected and vaccinated animals. The current multiplexed assay consists of synthetically produced peptide signatures 3A, 3B, and 3D and the recombinant protein signature 3ABC in combination with four controls. To determine the diagnostic specificity of each signature in the multiplex, the assay was evaluated against a naive population (n = 104) and a vaccinated population (n = 94). Subsequently, the multiplexed assay was assessed by using a panel of bovine sera generated by the World Reference Laboratory for foot-and-mouth disease in Pirbright, United Kingdom. This serum panel has been used to assess the performance of other singleplex enzyme-linked immunosorbent assay (ELISA)-based nonstructural protein antibody assays. The 3ABC signature in the multiplexed assay showed performance comparable to that of a commercially available nonstructural protein 3ABC ELISA (Cedi test), and additional information pertaining to the relative diagnostic sensitivity of each signature in the multiplex was acquired in one experiment. The encouraging results of the evaluation of the multiplexed assay against a panel of diagnostically relevant samples promote further assay development and optimization to generate an assay for routine use in foot-and-mouth disease serological surveillance.

* Corresponding author. Present address: MagIC Technologies, 463 S. Milpitas Blvd., Milpitas, CA 95035. Phone: (408) 935-1228. Fax: (408) 935-1393. E-mail: julie.perkins{at}magictech.com

{triangledown} Published ahead of print on 3 October 2007.

{dagger} Supplemental material for this article may be found at http://cvi.asm.org/.

Clinical and Vaccine Immunology, November 2007, p. 1472-1482, Vol. 14, No. 11
1071-412X/07/$08.00+0     doi:10.1128/CVI.00227-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»